Evidence map›Paper›PMID 38630333›Full record

ArticleJournal of cancer survivorship : research and practice2025

Trends in ototoxicity monitoring among cisplatin-treated patients with cancer.

David S Lee, Emma Y Travis, Susan K Wong, Marie-Ange Munyemana, Lauren Mueller, Cathryn Collopy Rowling, Jason T Rich, Patrik Pipkorn, Sidharth V Puram, Ryan S Jackson and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

David S LeeDepartment of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis, MO, 63110, USA. david.s.lee@wustl.edu.
Emma Y TravisDivision of Adult Audiology, Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Susan K WongDivision of Adult Audiology, Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Marie-Ange MunyemanaDepartment of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis, MO, 63110, USA.
Lauren MuellerDepartment of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis, MO, 63110, USA.
Cathryn Collopy RowlingDivision of Adult Audiology, Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Jason T RichDepartment of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis, MO, 63110, USA.
Patrik PipkornDepartment of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis, MO, 63110, USA.
Sidharth V PuramDepartment of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis, MO, 63110, USA.
Ryan S JacksonDepartment of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis, MO, 63110, USA.
Douglas R AdkinsDepartment of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Peter OppeltDepartment of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Wade L ThorstadDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Cameron C WickDepartment of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, 660 South Euclid Avenue, Campus, Box 8115, St. Louis, MO, 63110, USA.
Jose P ZevallosDepartment of Otolaryngology - Head and Neck Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Kate McClannahanDivision of Adult Audiology, Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Angela L MazulDepartment of Otolaryngology - Head and Neck Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Washington University in St. Louis · USUniversity of Pittsburgh · US

Funding

DEVELOPMENT OF CLINICIAN/RESEARCHERS IN ACADEMIC ENTT32DC000022 · NIDCD · WASHINGTON UNIVERSITY · PI PICCIRILLO, JAY F. · 1989 to 2022
$5.6M
Otolaryngology R25 Mentored Research Pathway at Washington UniversityR25DC020706 · NIDCD · WASHINGTON UNIVERSITY · PI Jay F. Piccirillo · 2023 to 2026
$1.6M
National Institute of Deafness and Other Communication Disorders (NIDCD) R25DC020706National Institute of Deafness and Other Communication Disorders (NIDCD) T32DC000022
6 · The paper itself

Abstract

purposeThis study aims to characterize patterns in ototoxicity monitoring and identify potential barriers to audiologic follow-up.

methodsWe performed a single-institution retrospective cohort study on adult (≥ 18 years old) cancer patients treated with cisplatin from January 2014 to September 2021. Our primary outcomes were rates of baseline and post-treatment audiograms at the following time points: 3, 6, 12, and greater than 12 months. Time-to-event analyses were performed to describe additional insights to ototoxicity monitoring patterns.

resultsNine hundred fifty-five patients with cancer were included for analysis. The most common primary cancer sites were head and neck (64%), followed by cervical (24%). Three hundred seventy-three patients (39%) underwent baseline audiometric assessment, 38 patients (4%) received audiologic evaluation during chemotherapy, and 346 patients (36%) obtained at least one post-treatment audiogram. Audiologic follow-up was greatest within 3 months of completing chemotherapy (26%), but this tapered dramatically to less than 10% at every other post-treatment time point. Patients with head and neck cancer achieved higher rates of audiologic follow-up at every time point than patients with non-head and neck cancer except for during treatment.

conclusionsOtotoxicity monitoring is an inconsistent practice, particularly during chemotherapy and for long-term surveillance of hearing loss. Patients with non-head and neck cancer may be at increased risk for loss of audiologic follow-up. IMPLICATIONS FOR CANCER SURVIVORS: Cisplatin ototoxicity is a common occurrence that can be effectively managed with auditory rehabilitation. Therefore, referrals to audiology and counseling on treatment-related ototoxicity are recommended throughout chemotherapy and cancer survivorship.

Indexed as

Antineoplastic AgentsCisplatinNeoplasmsOtotoxicityAdultAgedCancer SurvivorsFemaleHumansMaleMiddle AgedRetrospective StudiesAntineoplastic AgentsCisplatinCancerCisplatinHead and neck cancerOtotoxicityOtotoxicity monitoring

Identifiers

PMID38630333
OpenAlexW4394873026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.